Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that the company is now running on a different basis than its reported results and reputation were built on, with both halves: (1) a change of basis already real, and (2) management says the record and perception lag the change. Let's analyze the transcript. Key points from management: - Q4 revenue decreased 10% year-over-year, driven by decline in Advanced Wound Care and Surgical & Sports Medicine. - They mention challenges in physician office setting due to reimbursement uncertainty and competitive pressure from smaller amniotic players. - They highlight bright spots: excluding ReNu, NuCel, Dermagraft, they delivered low double-digit growth in accounts in hospital outpatient and physician office. Double-digit growth in Advanced Wound Care in hospital outpatient setting. - They discuss ReNu Phase 3 trial progress, interim analysis, enrollment completed. - They discuss pause of Canton manufacturing facility, and plan to bring Dermagraft and TransCyte back. - They discuss CMS town hall and future engagement. - Guidance for 2023: net revenue flat to up 2%, with Advanced Wound Care down 1% to up 1%, Surgical & Sports Medicine up 5-19%, PuraPly down 18-26%. Non-PuraPly products expected to grow ~28% at midpoint. - They mention that PuraPly has been published in ASP, causing a pause. They expect to overcome with growth of rest of portfolio. - They talk about competitive noise and confusion, but trends in 2023 so far encouraging. Now, does management describe the company as now operating on a genuinely different basis? They talk about a shift in product mix: PuraPly declining, non-PuraPly growing. They mention new product introductions, expansion into hospital outpatient, and growth in accounts. They also mention strategic repositioning of Surgical & Sports Medicine business. But is this a "change of basis" at the root? They are still selling advanced wound care products, but the mix is shifting. They are also dealing with reimbursement changes. However, they don't explicitly say "we are now a different kind of business." They talk about challenges and guidance.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...